Connie M Rhee1, Vanessa A Ravel1, Elani Streja1, Rajnish Mehrotra1, Steven Kim1, Jiaxi Wang1, Danh V Nguyen1, Csaba P Kovesdy1, Gregory A Brent1, Kamyar Kalantar-Zadeh1. 1. Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension (C.M.R., V.A.R., E.S., J.W., K.K.-Z.), University of California-Irvine, Orange, California 92868; Kidney Research Institute and Harborview Medical Center, Division of Nephrology (R.M.), University of Washington, Seattle, Washington 98195; Department of Mathematics and Statistics (S.K.), California State University-Monterey Bay, Seaside, California 93955; Department of Medicine (D.V.N.), University of California-Irvine, Orange, California 92868; University of Tennessee Health Science Center (C.P.K.), Memphis, Tennessee 38163; Memphis Veterans Affairs Medical Center (C.P.K.), Memphis, Tennessee 38104; and Department of Medicine (G.A.B.), David Geffen School of Medicine at UCLA, Los Angeles, California 90095.
Abstract
CONTEXT AND OBJECTIVE: End-stage renal disease patients have a higher risk of thyroid disease compared with those without kidney disease. Although thyroid dysfunction is associated with higher death risk in the general population and those undergoing hemodialysis, little is known about the effect of thyroid disease upon mortality in patients treated with peritoneal dialysis (PD). DESIGN, SETTING, PARTICIPANTS, AND MAIN OUTCOME: We examined the association of thyroid status, assessed by serum TSH, with all-cause mortality among PD patients from a large national dialysis organization who underwent one or more TSH measurements over 5 years (January 2007 to December 2011). Thyroid status was categorized as overt-hyperthyroid, subclinical-hyperthyroid, low-normal, high-normal, subclinical-hypothyroid, and overt-hypothyroid range (TSH < 0.1, 0.1–<0.5, 0.5–<3.0, 3.0–<5.0, 5.0–<10.0, and ≥10.0 mIU/L, respectively). We examined the association between TSH and mortality using case mix–adjusted time-dependent Cox models to assess short-term thyroid function–mortality associations and to account for changes in thyroid function over time. RESULTS: Among 1484 patients, 7 and 18% had hyperthyroidism and hypothyroidism, respectively, at baseline. We found that both lower and higher time-dependent TSH levels were associated with higher mortality (reference: TSH, 0.5-<3.0 mIU/L): adjusted hazard ratios (95% confidence intervals) 2.09 (1.08-4.06), 1.53 (0.87-2.70), 1.05 (0.75-1.46), 1.63 (1.11-2.40), and 3.11 (2.08-4.63) for TSH levels, <0.1, 0.1-<0.5, 0.5-<3.0, 3.0-<5.0, 5.0-<10.0, and ≥10.0 mIU/L, respectively. CONCLUSION: Time-dependent TSH levels < 0.1 mIU/L and ≥ 5.0 mIU/L were associated with higher mortality, suggesting hyper- and hypothyroidism carry short-term risk in PD patients. Additional studies are needed to determine mechanisms underlying the thyroid dysfunction-mortality association, and whether normalization of TSH with treatment ameliorates mortality in this population.
CONTEXT AND OBJECTIVE: End-stage renal diseasepatients have a higher risk of thyroid disease compared with those without kidney disease. Although thyroid dysfunction is associated with higher death risk in the general population and those undergoing hemodialysis, little is known about the effect of thyroid disease upon mortality in patients treated with peritoneal dialysis (PD). DESIGN, SETTING, PARTICIPANTS, AND MAIN OUTCOME: We examined the association of thyroid status, assessed by serum TSH, with all-cause mortality among PDpatients from a large national dialysis organization who underwent one or more TSH measurements over 5 years (January 2007 to December 2011). Thyroid status was categorized as overt-hyperthyroid, subclinical-hyperthyroid, low-normal, high-normal, subclinical-hypothyroid, and overt-hypothyroid range (TSH < 0.1, 0.1–<0.5, 0.5–<3.0, 3.0–<5.0, 5.0–<10.0, and ≥10.0 mIU/L, respectively). We examined the association between TSH and mortality using case mix–adjusted time-dependent Cox models to assess short-term thyroid function–mortality associations and to account for changes in thyroid function over time. RESULTS: Among 1484 patients, 7 and 18% had hyperthyroidism and hypothyroidism, respectively, at baseline. We found that both lower and higher time-dependent TSH levels were associated with higher mortality (reference: TSH, 0.5-<3.0 mIU/L): adjusted hazard ratios (95% confidence intervals) 2.09 (1.08-4.06), 1.53 (0.87-2.70), 1.05 (0.75-1.46), 1.63 (1.11-2.40), and 3.11 (2.08-4.63) for TSH levels, <0.1, 0.1-<0.5, 0.5-<3.0, 3.0-<5.0, 5.0-<10.0, and ≥10.0 mIU/L, respectively. CONCLUSION: Time-dependent TSH levels < 0.1 mIU/L and ≥ 5.0 mIU/L were associated with higher mortality, suggesting hyper- and hypothyroidism carry short-term risk in PDpatients. Additional studies are needed to determine mechanisms underlying the thyroid dysfunction-mortality association, and whether normalization of TSH with treatment ameliorates mortality in this population.
Authors: Christiaan L Meuwese; Olaf M Dekkers; Peter Stenvinkel; Friedo W Dekker; Juan J Carrero Journal: Nat Rev Nephrol Date: 2013-09-03 Impact factor: 28.314
Authors: Connie M Rhee; Steven Kim; Daniel L Gillen; Tolga Oztan; Jiaxi Wang; Rajnish Mehrotra; Sooraj Kuttykrishnan; Danh V Nguyen; Steven M Brunelli; Csaba P Kovesdy; Gregory A Brent; Kamyar Kalantar-Zadeh Journal: J Clin Endocrinol Metab Date: 2015-01-29 Impact factor: 5.958
Authors: Christiane Drechsler; Andreas Schneider; Lena Gutjahr-Lengsfeld; Matthias Kroiss; Juan Jesús Carrero; Vera Krane; Bruno Allolio; Christoph Wanner; Martin Fassnacht Journal: Am J Kidney Dis Date: 2013-12-04 Impact factor: 8.860
Authors: A J Jaroszyński; A Głowniak; B Chrapko; T Sodolski; T Małecka; T Widomska-Czekajska; A Ksiazek Journal: Physiol Res Date: 2005-01-10 Impact factor: 1.881
Authors: Christiaan L Meuwese; Juan J Carrero; Iván Cabezas-Rodríguez; Olof Heimburger; Peter Barany; Bengt Lindholm; Abdul R Qureshi; Jonaz Ripsweden; Friedo W Dekker; Peter Stenvinkel Journal: J Intern Med Date: 2013-07-15 Impact factor: 8.989
Authors: Connie M Rhee; Kamyar Kalantar-Zadeh; Vanessa Ravel; Elani Streja; Amy S You; Steven M Brunelli; Danh V Nguyen; Gregory A Brent; Csaba P Kovesdy Journal: Mayo Clin Proc Date: 2018-05 Impact factor: 7.616
Authors: Connie M Rhee; Amy S You; Danh V Nguyen; Steven M Brunelli; Matthew J Budoff; Elani Streja; Tracy Nakata; Csaba P Kovesdy; Gregory A Brent; Kamyar Kalantar-Zadeh Journal: J Clin Endocrinol Metab Date: 2017-05-01 Impact factor: 5.958
Authors: Connie M Rhee; Matthew Budoff; Gregory Brent; Amy S You; Peter Stenvinkel; Alejandra Novoa; Ferdinand Flores; Sajad Hamal; Christopher Dailing; April Kinninger; Tracy Nakata; Csaba P Kovesdy; Danh V Nguyen; Kamyar Kalantar-Zadeh Journal: Cardiorenal Med Date: 2022-05-12 Impact factor: 4.360
Authors: Giuseppe Stefano Netti; Mario Rotondi; Adelaide Di Lorenzo; Domenico Papantonio; Antonino Teri; Morena Schirone; Federica Spadaccino; Laura Croce; Barbara Infante; Rossella Perulli; Francesca Coperchini; Maria Teresa Rocchetti; Giuseppina Iannelli; Francesca Fortunato; Rosa Prato; Giuseppe Castellano; Loreto Gesualdo; Giovanni Stallone; Elena Ranieri; Giuseppe Grandaliano Journal: Clin Kidney J Date: 2020-02-10